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Background
Measures of glomerular filtration rate (GFR) showed
discordant results. CKD-EPI creatinine formula resulted
more accurate than other equations in subjects with
normal or mildly decreased renal function in the general
population and cystatin C could be even a more sensi-
tive measure. As for lipids, lipoprotein subfractions were
suggested to be more informative on the cardiovascular
risk than the commonly used cholesterol subfractions,
with protection conferred especially by HDLp-small
(Baker et al. JID 2010). Prospective evaluation of all
these markers upon initiation of standard HAART regi-
mens is lacking. We conducted a small, intensive, ran-
domized study in naïve HIV-infected patients comparing
TDF/FTC+ATV/r versus TDF/FTC+EFV as first-line
therapy for these novel markers.
Methods
Antiretroviral-naïve HIV-infected patients, recruited
from 4 centers in Italy (Brescia, Rome, Ferrara, Bari),
were randomized to ATV/r or EFV standard doses, in
combination with fixed-dose TDF/FTC. Patients had to
have creatinine clearance>50 ml/min. Outcome mea-
sures included serum creatinine and cystatin C levels
and derived eGFRs corrected for body surface area.
Lipoprotein particle size and concentration were
estimated using an NMR spectroscopy method at
Jochen-Hunter Lab., Germany.
Results
91 patients were randomized (48 ATV/r, 43 EFV; 80%
males; mean age 43 years; 4 patients class C; mean CD4
+2 8 3 / m m
3, SD: 119/mm
3). No significant differences
were found between the two arms at baseline, but for
some lipids (total cholesterol: mean 173 mg/dL ATV/r
vs. 156 mg/dL EFV; p=0.04; HDL-cholesterol: 44 mg/dL
v s .3 8m g / d L ;p = 0 . 0 0 7 ;H D L p :3 6m g / d Lv s .3 2m g / d L ;
p=0.02). At baseline, a correlation between CKD-EPI
creatinine and CKD-EPI cystatine C was found
(R2=0.51; p<0.0001). Through CKD-EPI creatinine for-
mula, we detected a significant decrease in eGFR from
baseline to week 48 in patients, receiving ATV/r
(-4.8233 mL/min/m
2;p = 0 . 0 0 2 )b u tn o ti nt h o s er e c e i v -
ing EFV. Greater GFR reductions were found with
CKD-EPI cystatin C than with CKD-EPI creatinine not
only in the ATV/r arm up to week 48 (-15.1388 mL/
min/m
2; p<0.0001), but also in the EFV arm from base-
l i n et ow e e k2 4( - 7 . 2 2 3 3m L / m i n / m
2;p = 0 . 0 4 ) .A sf o r
lipids, cholesterol subfractions increased more after EFV
than after ATV/r: mean increase from baseline to week
48 was 44.15 mg/dL vs. 15.51; p=0.002 for total choles-
terol, 32.4 mg/dL vs. 12.47 mg/dL; p=0.007 for LDL
cholesterol, 9.31 mg/dL vs. 2.13 mg/dL; p=0.002 for
HDL cholesterol. Total/HDL cholesterol ratio remained
stable in both arms. As for lipoprotein subfractions,
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(11.97 mg/dL vs. 7.97 mg/dL; p=0.03), but HDLp-small
increased significantly in both arms, without statistical
differences between the two (1.71 mg/dL vs. 1.86 mg/
dL).
Conclusions
Patients receiving TDF in combination with ATV/r had
greater decline in renal function than those receiving
TDF plus EFV, although eGFR decrease was small in
both arms. Interestingly, CKD-EPI cystatin C appeared
to be a stricter measure. As for lipids, EFV induced
greater LDL cholesterol increases but the risk appeared
to be counteracted by greater increase of both HDL-
cholesterol and HDLp, even though HDLp-small
increased similarly in the two arms. We suggest that
these novel measures provide additional information so
as to better characterize the toxicity profiles of the anti-
retroviral regimens.
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